



# Test Definition: GNPLT

Platelet Disorders, Comprehensive Gene Panel,  
Next-Generation Sequencing, Varies

## Overview

### Useful For

Evaluating hereditary platelet disorders in patients with a personal or family history suggestive of a hereditary platelet disorder

Diagnosing hereditary platelet disorders for patients in whom phenotypic testing is nondiagnostic but there is a strong clinical suspicion of the hereditary platelet disorder

Confirming a hereditary platelet disorder diagnosis with the identification of a known or suspected disease-causing alteration in one or more of 70 genes associated with a variety of hereditary platelet disorders

Determining the disease-causing alterations within one or more of these 70 genes to delineate the underlying molecular defect in a patient with a laboratory diagnosis of a platelet disorder

Identifying the causative alteration for genetic counseling purposes

Prognosis and risk assessment based on genotype-phenotype correlations

Providing a prognosis in syndromic hereditary platelet disorders

Carrier testing for close family members of an individual with a hereditary platelet disorder diagnosis

This test is **not intended for** prenatal diagnosis.

### Reflex Tests

Test Id	Reporting Name	Available Separately	Always Performed
CULFB	Fibroblast Culture for Genetic Test	Yes	No

### Genetics Test Information

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 70 genes associated with a variety of hereditary platelet disorders: *ABCC4*, *ABCG5*, *ABCG8*, *ACTB*, *ACTN1*, *ANKRD26*, *ANO6*, *AP3B1*, *AP3D1*, *ARPC1B*, *BLOC1S3*, *BLOC1S5*, *BLOC1S6*, *CDC42*, *CYCS*, *DIAPH1*, *DTNBP1*, *ETV6*, *FERMT3*, *FLI1*, *FLNA*, *FYB1*, *GATA1*, *GATA2*, *GFI1B*, *GNE*, *GP1BA*, *GP1BB*, *GP6*, *GP9*, *HOXA11*, *HPS1*, *HPS3*, *HPS4*, *HPS5*, *HPS6*, *IKZF5*, *ITGA2B*, *ITGB3*, *KDSR*, *LYST*, *MASTL*, *MECOM*, *MPIG6B*, *MPL*, *MYH9*, *NBEA*, *NBEAL2*, *ORAI1*, *P2RY1*, *P2RY12*, *PLA2G4A*, *PLAU*, *PRKACG*, *PTGS1*, *RASGRP2*, *RBM8A*, *RUNX1*, *SLFN14*, *SRC*, *STIM1*, *STXBP2*, *TBXA2R*, *TBXAS1*, *THPO*, *TPM4*, *TUBB1*, *VIPAS39*, *VPS33B*, and *WAS*. See [Targeted Genes and Methodology Details for Platelet Disorders Comprehensive Gene Panel](#) and Method Description for additional details.

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk

---

assessment, familial screening, and genetic counseling for a variety of hereditary platelet disorders.

**Testing Algorithm**

The clinical workup for detecting inherited platelet disorders should begin with a careful review of the complete blood cell count and peripheral blood smear results as well as other platelet tests, such as light transmission platelet aggregometry electrical impedance whole blood aggregometry, platelet function analyzer 100 (PFA-100), platelet transmission electron microscopy (TEM), and platelet flow cytometric analysis. TEM is an essential tool for laboratory diagnosis of various hereditary platelet disorders that have ultrastructural abnormalities, such as gray platelet syndrome. Flow cytometry is the preferred method to assess hereditary platelet disorders due to quantitative surface glycoprotein deficiencies.

Platelet laboratory testing may not be able to identify all inherited platelet disorders. Occasionally, the clinical picture may be consistent with a defect in primary hemostasis, but the results of platelet function tests may be normal or non-diagnostic.

Genetic testing for hereditary platelet disorders is indicated if:

- Platelet tests indicate a deficiency or functional abnormality
- There is a clinical suspicion for a hereditary platelet disorder due to family history or patient's clinical presentation
- Acquired causes of deficiencies associated with platelet disorders have been excluded

If a platelet disorder is a concern, a set of clinical guidelines from the British Society for Haematology on testing for heritable platelet disorders is freely available.(1)

**Skin biopsy or cultured fibroblast specimens:** For skin biopsy or cultured fibroblast specimens, a fibroblast culture will be performed at an additional charge. If viable cells are not obtained, the client will be notified.

**Special Instructions**

- [Informed Consent for Genetic Testing](#)
- [Platelet Esoteric Testing Patient Information](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)
- [Targeted Genes and Methodology Details for Platelet Disorders, Comprehensive Gene Panel](#)

**Method Name**

Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing

**NY State Available**

Yes

**Specimen****Specimen Type**

Varies

---

**Ordering Guidance**

The test is designed to evaluate a variety of hereditary platelet disorders and to be utilized for genetic confirmation of a phenotypic diagnosis of a hereditary platelet disorder.

This test is not designed to evaluate hereditary bleeding disorders. For patients with clinical suspicion of an inherited bleeding disorder, it is important to exclude plasmatic factor deficiencies eg, von Willebrand disease, hemophilia, or other factor deficiencies prior to considering an inherited platelet function defect. If bleeding is the indication for testing and testing for hereditary bleeding disorders is desired, bleeding panels are available. See GNBLF / Bleeding Disorders, Focused Gene Panel, Next-Generation Sequencing, Varies or GNBLC / Bleeding Disorders, Comprehensive Gene Panel, Next-Generation Sequencing, Varies.

For assessment of hereditary platelet disorders that have ultrastructural abnormalities, such as gray platelet syndrome, order PTEM / Platelet Transmission Electron Microscopic Study, Whole Blood.

For assessment of hereditary platelet disorders due to quantitative surface glycoprotein deficiencies, order PLAFL / Platelet Surface Glycoprotein, Flow Cytometry, Blood.

Targeted testing for familial variants (also called site-specific or known variants testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

**Necessary Information**

[Platelet Esoteric Testing Patient Information](#) is required. Testing may proceed without the patient information; however, the information aids in providing a more thorough interpretation. Ordering healthcare professionals are strongly encouraged to fill out the form and send with the specimen.

**Specimen Required**

**Patient Preparation:** A previous bone marrow transplant from an allogenic donor will interfere with testing. For information about testing patients who have received a bone marrow transplant, call 800-533-1710.

**Submit only 1 of the following specimens:**

**Specimen Type:** Whole blood

**Container/Tube:**

**Preferred:** Lavender top (EDTA)

**Acceptable:** Yellow top (ACD)

**Specimen Volume:** 3 mL

**Collection Instructions:**

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**

**Specimen Stability Information:** Ambient (preferred) 4 days/Refrigerated 4 days

**Additional Information:** To ensure minimum volume and concentration of DNA are met, the requested volume must be submitted. Testing may be canceled if DNA requirements are inadequate.

**Specimen Type:** Skin biopsy

**Supplies:** Fibroblast Biopsy Transport Media (T115)

**Container/Tube:** Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin.

**Specimen Volume:** 4-mm punch

**Specimen Stability Information:** Refrigerated (preferred) 24 hours/Ambient 24 hours

**Additional Information:**

1. Specimens are preferred to be received within 24 hours of collection. Culture and extraction will be attempted for specimens received after 24 hours and will be evaluated to determine if testing may proceed.
2. A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks are required to culture fibroblasts before genetic testing can occur.

**Specimen Type:** Cultured fibroblasts

**Source:** Skin or tissue

**Container/Tube:** T-25 flask

**Specimen Volume:** 2 Flasks

**Collection Instructions:** Submit confluent cultured fibroblast cells from a skin biopsy from another laboratory. Cultured cells from a prenatal specimen will not be accepted.

**Specimen Stability Information:** Ambient (preferred) 24 hours/Refrigerated 24 hours

**Additional Information:**

1. Specimens are preferred to be received within 24 hours of collection. Culture and extraction will be attempted for specimens received after 24 hours and will be evaluated to determine if testing may proceed.
2. A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks are required to culture fibroblasts before genetic testing can occur.

## Forms

1. [Platelet Esoteric Testing Patient Information](#) is required.
2. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available:
  - [Informed Consent for Genetic Testing](#) (T576)
  - [Informed Consent for Genetic Testing \(Spanish\)](#) (T826)
3. If not ordering electronically, complete, print, and send an [Coagulation Test Request](#) (T753) with the specimen.

## Specimen Minimum Volume

Blood: 1 mL; Cultured fibroblasts/skin biopsy: see Specimen Required

## Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

---

**Clinical & Interpretive****Clinical Information**

Platelets have essential roles in primary hemostasis. Patients with either hereditary or acquired platelet disorders usually have bleeding diathesis, which can potentially be life threatening and may also have issues with the development and/or functioning of major organs.(2) Inherited platelet disorders can be syndromic (ie, associated with current or future development of other organ system defects) or non-syndromic (ie, isolated to thrombocytopenia with no other organ system defects).

A reliable laboratory diagnosis of a platelet disorder can significantly impact patients' and, potentially, their family members' clinical management and outcome. Identification of an alteration that is known or suspected to cause disease aids in confirmation of the diagnosis and potentially provides prognostic information especially in the syndromic inherited platelet disorders.

This panel evaluates 70 genes associated with a variety of hereditary platelet disorders, including reduced adenosine diphosphate (ADP)-induced platelet aggregation; Baraitser-Winter syndrome 1 with macrothrombocytopenia; Scott syndrome; Hermansky-Pudlak syndrome; platelet abnormalities with eosinophilia and immune-mediated inflammatory disease; Takenouchi-Kosaki syndrome with thrombocytopenia; leukocyte integrin adhesion deficiency type III; Paris-Trousseau-Jacobsen syndrome; *GATA2* deficiency; Bernard-Soulier syndrome; platelet-type von Willebrand disease; bleeding diathesis due to glycoprotein VI deficiency; Glanzmann thrombasthenia; Chediak-Higashi syndrome; congenital amegakaryocytic thrombocytopenia; May-Hegglin disorder/anomaly; Sebastian syndrome; *MYH9*-related disorders; autism with platelet dense granule defect; gray platelet syndrome; autosomal dominant tubular aggregate myopathy-2; ADP receptor defect; deficiency of phospholipase A2 group IV A; Quebec platelet disorder; aspirin-like defect; thrombocytopenia-absent radius syndrome; familial platelet disorder with predisposition to acute myeloid leukemia; Stormorken syndrome; York platelet syndrome; familial hemophagocytic lymphohistiocytosis type 5; thromboxane A2 receptor defect; Ghosal syndrome; ARC (arthrogryposis, renal dysfunction, and cholestasis) syndromes 1 and 2; Wiskott-Aldrich syndrome; a variety of platelet-type bleeding disorders; and hereditary/congenital thrombocytopenias, such as various macrothrombocytopenias. These congenital thrombocytopenias include sitosterolemia with macrothrombocytopenia; macrothrombocytopenia and sensorineural hearing loss; thrombocytopenia and susceptibility to cancer; X-linked thrombocytopenia with dyserythropoiesis; myopathy associated with thrombocytopenia; amegakaryocytic thrombocytopenia with radioulnar synostoses 1 and 2; thrombocytopenia and erythrokeraderma; thrombocytopenia anemia and myelofibrosis; and thrombocytopenia progressing to trilineage bone marrow failure.

The risk of developing bleeding or other phenotypic features associated with these disorders and syndromes varies. Several of the genes on this panel have established bleeding, thrombocytopenia, and other hematologic or nonhematologic disease associations. Several of the genes on this panel also have expert group guidelines.(1,3-5)

It is recommended that genetic testing be offered to all patients suspected of having a heritable platelet disorder since some patients may have normal platelet laboratory testing results.(1,6)

**Reference Values**

An interpretive report will be provided.

**Interpretation**

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.<sup>(7)</sup> Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

**Cautions**

Clinical Correlations:

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

If testing was performed because of a clinically significant family history, it is often useful to first test an affected family member. Detection of a reportable variant in an affected family member would allow for more informative testing of at-risk individuals.

To discuss the availability of additional testing options or for assistance in the interpretation of these results, contact the Mayo Clinic Laboratories genetic counselors at 800-533-1710.

Technical Limitations:

Next-generation sequencing may not detect all types of genomic variants. In rare cases, false-negative or false-positive results may occur. The depth of coverage may be variable for some target regions; assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. Confirmation of select reportable variants will be performed by alternate methodologies based on internal laboratory criteria.

This test is validated to detect 95% of deletions up to 75 base pairs (bp) and insertions up to 47 bp. Deletions-insertions (delins) of 40 or more bp, including mobile element insertions, may be less reliably detected than smaller delins.

This analysis targets single and multi-exon deletions/duplications; however, in some instances, single exon resolution cannot be achieved due to isolated reduction in sequence coverage or inherent genomic complexity. Balanced structural rearrangements (such as translocations and inversions) may not be detected.

Deletion/duplication events that extend past the genes included on the panel may occur. In these instances, genes included in the ordered test are provided on the report and interpreted, and genomic breakpoints are reported if they are confirmed. However, copy number variants for genes not listed in the Method Description are typically not reported or interpreted for haploinsufficiency/triplosensitivity. CMACB / Chromosomal Microarray, Congenital, Blood; WESPR / Panel to Whole Exome Sequencing Reflex Test, Varies; or WGSDX / Whole Genome Sequencing for Hereditary Disorders, Varies is recommended for a full interpretation of deletions/duplications predicted to extend past the genes included on the panel.

---

This test is not designed to detect low levels of mosaicism or differentiate between somatic mutations and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

For detailed information regarding gene specific performance and technical limitations, see Method Description or contact a laboratory genetic counselor.

If the patient has had an allogeneic hematopoietic stem cell transplant or a recent blood transfusion, results may be inaccurate due to the presence of donor DNA. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.

#### Reclassification of Variants:

Currently, it is not standard practice for the laboratory to systematically review previously classified variants on a regular basis. The laboratory encourages healthcare professionals to contact the laboratory at any time to learn how the classification of a particular variant may have changed over time. Due to broadening genetic knowledge, it is possible that the laboratory may discover new information of relevance to the patient. Should that occur, the laboratory may issue an amended report.

#### Variant Evaluation:

Evaluation and categorization of variants are performed using published American College of Medical Genetics and Genomics and the Association for Molecular Pathology recommendations as a guideline.<sup>(7)</sup> Other gene-specific guidelines may also be considered. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance. Variants classified as benign or likely benign are not reported.

Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and periodic updates to these tools may cause predictions to change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgment.

Rarely, incidental or secondary findings may implicate another predisposition or presence of active disease. These findings will be carefully reviewed to determine whether they will be reported.

#### Clinical Reference

1. Gomez K, Anderson J, Baker P, et al. Clinical and laboratory diagnosis of heritable platelet disorders in adults and children: a British Society for Haematology Guideline. *Brit J Haematol*. 2021;195(1):46-72
2. Nurden AT, Freson K, Selifsohn U. Inherited platelet disorders. *Haemophilia*. 2012;18(s4):154-160
3. International Society on Thrombosis and Haemostasis. Bleeding Thrombotic and Platelet Disorder TIER1 genes. ISTH; 2018. Updated July 2024. Accessed March 2, 2026. Available at: [www.isth.org/page/GinTh\\_GeneLists](http://www.isth.org/page/GinTh_GeneLists)
4. Megy K, Downes K, Simeoni I, et al. Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH. *J Thromb Haemost*. 2019;17(8):1253-1260
5. Bolton-Maggs PHB, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. *Brit J Haematol*. 2006;135(5):603-633

- 
6. Watson SP, Lowe GC, Lordkipanidze M, Morgan NV, GAPP consortium. Genotyping and phenotyping of platelet function disorders. *J Thromb Haemost.* 2013;11 Suppl 1:351-363
7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-424

## Performance

### Method Description

Next-generation sequencing (NGS) and/or Sanger sequencing is performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known disease-causing variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for deletions-insertions (delins) less than 40 base pairs (bp), and above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of deletions and duplications in the genes analyzed.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. See [Targeted Genes and Methodology Details for Platelet Disorders Comprehensive Gene Panel](#) and Methodology Details for details regarding the targeted genes analyzed for each test and specific gene regions not routinely covered. (Unpublished Mayo method)

Reference transcript numbers may be updated due to transcript re-versioning. Always refer to the final patient report for gene transcript information referenced at the time of testing. Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

Genes analyzed: *ABCC4, ABCG5, ABCG8, ACTB, ACTN1, ANKRD26, ANO6, AP3B1, AP3D1, ARPC1B, BLOC1S3, BLOC1S5, BLOC1S6, CDC42, CYCS, DIAPH1, DTNBP1, ETV6, FERMT3, FLI1, FLNA, FYB1, GATA1, GATA2, GFI1B, GNE, GP1BA, GP1BB, GP6, GP9, HOXA11, HPS1, HPS3, HPS4, HPS5, HPS6, IKZF5, ITGA2B, ITGB3, KDSR, LYST, MASTL, MECOM, MPIG6B, MPL, MYH9, NBEA, NBEAL2, ORAI1, P2RY1, P2RY12, PLA2G4A, PLAU, PRKACG, PTGS1, RASGRP2, RBM8A, RUNX1, SLFN14, SRC, STIM1, STXBP2, TBXA2R, TBXAS1, THPO, TPM4, TUBB1, VIPAS39, VPS33B, and WAS*

### PDF Report

Supplemental

### Day(s) Performed

Varies

### Report Available

28 to 42 days

### Specimen Retention Time

Whole blood: 2 weeks (if available); Cultured fibroblasts: 1 month; Extracted DNA: 3 months

## Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Main Campus

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

### CPT Code Information

81443

88233-Tissue culture, skin, solid tissue biopsy (if appropriate)

88240-Cryopreservation (if appropriate)

### LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
GNPLT	Platelet Comprehensive Panel, NGS	105334-7

Result ID	Test Result Name	Result LOINC® Value
619286	Test Description	62364-5
619287	Specimen	31208-2
619288	Source	31208-2
619289	Result Summary	50397-9
619290	Result	82939-0
619291	Interpretation	59465-5
619292	Additional Results	82939-0
619293	Resources	99622-3
619294	Additional Information	48767-8
619295	Method	85069-3
619296	Genes Analyzed	82939-0
619297	Disclaimer	62364-5
619298	Released By	18771-6